return equiti ttm
billion consensu estim billion segment organ
revenu increas life scienc diagnost dental
environment appli solut adjust ep increas year-over-year
consensu estim
geograph danah china busi continu drive growth region
report double-digit growth ninth straight quarter growth broad-
base four compani segment record double-digit growth region
first quarter
guidanc manag introduc second quarter adjust ep guidanc rang
translat year-over-year consensu estim
prior releas manag forecast core revenu growth second
quarter full year manag lower adjust ep guidanc
rang previous consensu estim releas
reduct high end rang reflect dilut
equiti issuanc relat pend acquisit first-quart
earn beat compar high end manag guidanc rang
midpoint updat full-year guidanc repres growth year-over-year
valuat conclus trade time adjust ep
estim look current consensu estim adjust ep
believ estim alreadi account acquisit
expect estim increas anoth follow closur deal
use assumpt share trade approxim time potenti adjust ep
line peer group higher-growth diversifi industri
believ continu deserv modest valuat premium group given
expect above-averag growth rate high qualiti depend
compani earn longer term expect share appreci line
annual earn growth estim low- midteen rang includ
accret futur acquisit result maintain outperform rate
forecast shown tabl follow page lower earn
estim primarili driven expect share dilut
diversifi global scienc technolog compani design manufactur market divers
line industri healthcare-rel product four strateg platformslif scienc diagnost
dental environment appli solut recur revenu account sale product
produc sold world-wide north america sale western europ develop
region high-growth market
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
segment detail growth rate refer section core growth rate
life scienc first-quart sale revenu increas year-over-year includ double-digit growth
beckman life scienc high-single-digit growth lecia microsystem low-single-digit growth sciex high-
single-digit growth pall manag note acquir april continu exceed initi
expect segment adjust oper margin expand basi point
diagnost first-quart sale revenu increas year-over-year includ midsingle-digit growth
beckman diagnost high-single-digit growth radiomet high-single-digit growth leica biosystem
cepheid slightli year-over-year segment face difficult comparison particularli strong first
quarter driven flu season segment adjust oper margin contract basi point
first quarter primarili due unfavor chang foreign exchang rate
op figur billion except per-shar consensu figur immedi prior earn releasesourc factset william blair estimatesdanah forecastwb forecasti life revenu oper diagnosticsrevenu revenu oper revenu oper environment appli solutionsrevenu revenu oper compani dataiii dentalcompon platform sale growth william blair
dental first-quart sale revenu increas year-over-year manag note north american
end-market appear stabil segment adjust oper margin contract basi point year-over-year
driven on-going invest new product develop remain track complet spin-
segment second half
environment appli solut first-quart sale revenu increas year-over-year
includ low-single-digit growth product identif midsingle-digit growth videojet flat revenu
packag high-single-digit growth water qualiti segment adjust oper margin expand basi
point
margin gross margin contract basi point year-over-year adjust oper expens term dollar
increas year-over-year expand basi point percentag sale result factor
adjust oper margin contract basi point year-over-year oper margin expand basi
point year-over-year first quarter manag comment first-quart core margin would roughli
basi point year-over-year exclud headwind foreign currenc translat
balanc sheet cash flow first quarter gener free cash flow million year-
over-year result free-cash-flow-to-adjusted-net-incom convers ratio end first quarter
debt-to-capit ratio compani investor day decemb note
taken debt level around time ebitda financ acquisit past given healthi cash flow gener
abil de-lev quickli number would unreason look forward prior announc
agreement acquir translat roughli billion capac opportun head
pend acquisit includ cash purchas price billion expect fund approxim
billion proce equiti offer complet first quarter remaind cash hand
april acquir integr dna technolog purchas price billion provid
high-valu consum genom applic molecular biolog qpcr next-gener sequenc synthet biolog
gene edit molecular diagnost idt primari busi manufactur high-qual custom dna rna
oligonucleotid purchas price repres multipl time estim ebitda approxim
million expect gener revenu greater million anticip busi
grow core revenu double-digit-plu rate annual manag expect earn double-digit rang
year six acquisit expect accret adjust ep
februari announc agreement ge ge outperform acquir biopharma busi ge
life scienc cash purchas price approxim billion account anticip tax benefit net
purchas price deal approxim billion repres multipl approxim time expect
ebitda view reason valuat provid instrument consum
softwar support research discoveri process develop manufactur workflow biopharmaceut ge
biopharma expect gener revenu billion estim equat approxim
total sale transact expect close fourth quarter estim acquisit
accret adjust ep approxim first full year follow deal close incorpor
contribut acquisit model deal close
exhibit follow page highlight major acquisit recent year
datetargetplatformoverviewestim price million sale prior year million price/salesfeb technologywith headquart westlak ohio radiomet develop manufactur distribut technolog advanc critic care test system blood ga electrolyt metabolit compani offer complet solut complex process blood technologyth acquisit gendex mark entri dental busi gendex divis dentspli inc headquart de plain illinoi gendex lead manufactur dental imag product includ intra-or technologykaltenbach voight gmbh headquart biberach germani world-wide leader design manufactur sale dental equip includ handpiec treatment unit diagnost system laboratori ontario canada trojan inc lead water treatment technolog compani largest instal base ultraviolet water treatment system oper around rmselectron testwith headquart cleveland ohio cardin radiat manag servic provid solut maintain safe regulatory-compli facil medic imag therapi print plcproduct identificationlinx headquart st ive cambridgeshir uk major player global code mark industri suppli focus rang industri non-contact code mark equip base inkjet laser testwith primari oper unit kingdom austria produc sell comprehens array electr measur solut use commerci industri medic technologywith primari oper charlott north carolina newberg oregon pelton manufactur sell broad rang dental equip includ treatment unit light steril cabinetri dental microsystemsmed technologybas germani leica microsystem lead global design produc innov high- precis imag system use life scienc relat networkselectron testbas rockvil maryland visual network lead provid network test applic perform manag solut becom part fluke network busi technologywith headquart newport beach california sybron dental specialti manufactur high technolog dental dental implant infect prevent product dental restor orthodont endodont infect prevent systemsmed technologyvis system base australia manufactur market autom instrument biochem reagent detect cancer infecti diseas compani possess valuabl intellectu properti associ instrument reagent glen allen virginia chemtreat manufactur water treatment product chemic industri water treatment applic testbas beaverton oregon tektronix lead supplier test measur monitor product enabl design manufactur manag next-gener global commun network comput advanc technolog focu commun comput semiconductor consum electron military/aerospac educ industri group plcmedic technologygenetix headquart new milton hampshir uk provid scientist clinician solut imag intellig imag analysi facilit develop pharmaceut biotherapeut mainstream research clinic sciex md inc medic technologycalifornia-bas ab sciex lead design manufactur mass spectromet instrument use indentifi quantifi specif molecul specif sampl typic applic includ proteom research drug develop food environment safeti test diagnost test molecular devic suppli high-perform bioanalytical instrument system consum acceler improv research product effect life scienc research drug instrumentselectron testohio-bas keithley instrument design develop manufactur market complex electron instrument system gear special need engin electron manufactur academ institut research product develop high-perform product test process idwith headquart ghent belgium eskoartwork full-servic solut provid digit packag design product market eskoartwork suit softwar hardwar solut help custom reduc digit design cycl time ensur integr throughout packag materi suppli chain coulter inc life scienc diagnosticsbas brea california beckman coulter design manufactur market laboratori system includ instrument chemistri softwar suppli biomed laboratori need product use rang applic pioneer medic research drug discoveri diagnost system found hospit physician incorporatedproduct idx-rit global leader color scienc technolog compani includ design industri color leader panton llc develop manufactur market support innov color solut measur system softwar color standard inc life scienc diagnosticsbas chatsworth california iri inc lead global vitro diagnost compani focus product analyz particl live cell form structur morpholog varieti bodi biocaredentalheadquart switzerland nobel biocar manufactur dental implant cad/cam-bas prosthet restor aesthet dental medic productslif scienc diagnosticsheadquart cincinnati oh devicor global leader anatom patholog laboratori solut instrument special breast biopsi insutr consum microbiologylif scienc diagnosticsth microbiolog piec siemen healthcar busi establish leader microbi identif antibiot sensit test id/ast sciencespal lead provid filtrat separ purif solut remov contamin separ substanc varieti solid liquid lead innov global molecular diagnost compani develop manufactur market accur easi use molecular system sciencesphenomenex manufactur distributor high-valu consum separ scienc compani lead player proprietari chromatographi dna life sciencesidt provid high-valu consum genom applic molecular biolog qpcr next gener sequenc synthet biolog gene edit molecular biopharmalif sciencesg biopharma lead provid instrument consum softwar support research discoveri process develop manufactur workflow biopharmaceut drug compani report william blair estimateschronolog major acquisit william blair
incom wb tax net ni share ep cont ebitda saleslif appli oper appli segment oper margin adjust amort expens sourc compani data william blair estimatesdanah varianc tabl william blair
life appli actualconsensusnewpreviousconsensu revenu adjust adj ebitda adjust consensu figur immedi prior earn releasesourc compani report william blair epsfre revenu segment fy summaryresultsguidancefre operatingmarginadjustedebitdadanah corpor flash analyticsfisc first quarter earningstot revenu adj oper margingadj scienc diagnost dental environment appli solut william blair
danah corp rate outperformapril model thousand except per-shar item fiscal year end statement net good ex restr oper intang expens tax net discontinu convert prefer stock avail amort intang after-tax non-recurring expens net epsaverag dilut share dilut ep continu intang incom dilut tax tax sale net good ex restr oper net rate net good ex restr oper net dilut compani data william blair estim william blair
analysisseg saleslif environment appli total net segment sale growthlif appli segment total segment saleslif appli segment segment oper profitlif environment appli total segment total adjust oper report segment oper profit marginlif appli total segment oper profitlif appli segment oper increment oper marginlif appli increment oper increment oper marginlif appli increment oper compani data william blair estimatesdanah corpor nyse thousand except per share import disclosur
